FDA clarifies potential actions when onsite inspections are infeasible
Regulatory NewsJoanne S. Eglovitch
Audit/inspectionComplianceNorth AmericaPharmaceuticalsQuality Assurance and ControlRegulatory Intelligence/PolicyRegulatory NewsJoanne S. EglovitchAudit/inspectionComplianceNorth AmericaPharmaceuticalsQuality Assurance and ControlRegulatory Intelligence/Policy